ACRUX LIMITED — Capital/Financing Update 2021

Nov 10, 2021

==> picture [83 x 79] intentionally omitted <==

ASX Release

11 November 2021

Receipt of R&D Tax Incentive Rebate

Melbourne, Australia; 11 November 2021 Acrux Limited (ASX:ACR, “ Acrux ” or the “ Company ”) is pleased to announce that the Company has received $3,073,285 from the Australian Tax Office in relation to its R&D Tax Incentive Rebate for the 2020/2021 financial year.

The R&D Tax Incentive is an Australian Federal Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

General enquiries

Michael Kotsanis Acrux Limited CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au